前列地尔和丹参治疗急性脑梗死115例临床对照研究

A clinical study of alprostadil vs salvia miltiorrhiza in treatment of 115 patients with cerebral infarction

目的比较前列地尔和丹参注射液对急性脑梗死的治疗作用。方法将115例急性脑梗死患者分为前列地尔组(61例)和丹参组(54例),观察两组患者临床神经功能缺损情况和病情程度,检测血小板聚集率等。结果两组患者在用药后第7、14、21和90天神经功能缺损评分和日常生活活动Barthel指数与前一观察日的差异均有统计学意义(P值均<0．05)。与丹参组比较,前列地尔组患者神经功能恢复较早,且增幅明显,在用药后第21和90天两组增幅的差异有显著性(P值均<0．05)。治疗后两组血小板聚集率均较治疗前有明显改善(P值均<0．01),且前列地尔组较丹参组下降更为明显(P<0．01)。两组用药后不良反应均轻微。结论与丹参相比,前列地尔治疗急性脑梗死安全性高、疗效更确切。

Objective To compare the therapeutic effects of alprostadil and salvia miltiorrhiza injection in treating cerebral infarction. Methods Patients with cerebral infarction （n =115）were allocated into two groups： alprostadil group（61 patients） and miltiorrhiza group （54 patients）. Observation on clinical neurofunetional disorder and severity was carried out. Results According to the Chinese Stroke Scale and the Barthel Score, we found that there were definite effectiveness and statistical significances in the patients of the two groups after the 7th, 14th, 21st, 90th days of treatment comparing to those prior to the treatment. There were also significant differences between the above two groups regarding the efficacies of alprostadil and salvia miltiorrhiza at the 21st and 90th days （P 〈 0.05）, of which the improvement of Chinese Stroke Scale and the Barthel Score came earlier and being more effective in the alprostadil group since the 2nd day. Concomitantly, inhibition of platelet aggregation of the alprostadil group also improved more significantly （P〈 0.01）. Adverse reactions were modest in all patients. Conehtsion Alprostadil is safe and being more effective in treatment of cerebral infarction. （Shanghai Med J, 2007, 30：94-96）